Xeris Biopharma Holdings, Inc. Share Price
XERSXeris Biopharma Holdings, Inc. Stock Performance
Open $6.05 | Prev. Close $6.01 | Circuit Range N/A |
Day Range $6.05 - $6.17 | Year Range $4.25 - $10.07 | Volume 16,454 |
Average Traded $6.11 |
Xeris Biopharma Holdings, Inc. Share Price Chart
About Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Xeris Biopharma Holdings, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
28-Apr-26 | $6.13 | $6.09 | -0.57% |
27-Apr-26 | $6.03 | $6.13 | +1.07% |
24-Apr-26 | $5.97 | $6.06 | +1.85% |
23-Apr-26 | $5.98 | $5.95 | -1.49% |
22-Apr-26 | $5.90 | $6.04 | +2.37% |
21-Apr-26 | $6.25 | $5.90 | -5.52% |
20-Apr-26 | $6.30 | $6.25 | -1.96% |